<DOC>
	<DOC>NCT01186068</DOC>
	<brief_summary>The purpose of this study is to evaluate the dose-response relationship (effect) of four concentrations of V-101 Cream in patients with erythematous(redness) rosacea.</brief_summary>
	<brief_title>Dose Response Study of Patients With Erythematous Rosacea</brief_title>
	<detailed_description>Patients must have moderate to severe erythematous (facial redness) rosacea - Male and female patients must be at least 18 years old and in good general health - Female patients must not be pregnant or nursing</detailed_description>
	<mesh_term>Rosacea</mesh_term>
	<criteria>male or females at least 18 years of age diagnosis of stable erythematous rosacea &lt; 3 inflammatory lesions in good general health females must be nonpregnant and nonlactating must be willing to sign a consent form have ocular, phymatous or other types of rosacea allergy to any ingredient in study drug participation in other investigational studies within 30 days of enrollment use of systemic steroids within 28 days of Baseline use of tetracycline antibiotics within 28 days of baseline use of products containing oxymetazoline within 14 days of baseline use of topical steroids witin treatment area 14 days prior to baseline use of Rx or OTC products for treatment of acne or rosacea within 14 days of baseline use of any product for reducing redness within the treatment area witin 14 days prior to baseline use of monoamine oxidase (MAO) inhibitors use of niacin &gt;/= 500mg/day</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2010</verification_date>
	<keyword>Rosacea, erythema</keyword>
</DOC>